Theranostic nanoparticles
- PMID: 25413134
- PMCID: PMC4255955
- DOI: 10.2967/jnumed.114.146019
Theranostic nanoparticles
Abstract
Theranostic nanoparticles hold the potential to revolutionize disease management. Over the last decade, there has been growing interest in the engineering of various kinds of theranostic nanoparticles for simultaneous cancer imaging and therapy in small animals. Efficient targeting of theranostic nanoparticles to the tumor site is critical for both diagnosis and therapy. However, difficulties still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor-targeting capabilities. Here, we discuss the current and prospective status of theranostic nanoparticles that actively target tumors, as well as the challenges that still exist.
Keywords: active targeting; cancer; nanomedicine; theranostic nanoparticle; theranostics.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Conflict of interest statement
Figures



Similar articles
-
In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.ACS Nano. 2015;9(4):3926-34. doi: 10.1021/nn507241v. Epub 2015 Apr 8. ACS Nano. 2015. PMID: 25843647 Free PMC article.
-
Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy.Mini Rev Med Chem. 2017;17(18):1746-1757. doi: 10.2174/1389557516666160219122524. Mini Rev Med Chem. 2017. PMID: 26891932 Review.
-
Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.Acc Chem Res. 2011 Oct 18;44(10):1094-104. doi: 10.1021/ar200105p. Epub 2011 Aug 3. Acc Chem Res. 2011. PMID: 21812415 Review.
-
Oligonucleotide-based theranostic nanoparticles in cancer therapy.Nanomedicine (Lond). 2016 May;11(10):1287-308. doi: 10.2217/nnm-2016-0035. Epub 2016 Apr 22. Nanomedicine (Lond). 2016. PMID: 27102380 Free PMC article. Review.
-
Echogenic Glycol Chitosan Nanoparticles for Ultrasound-Triggered Cancer Theranostics.Theranostics. 2015 Oct 18;5(12):1402-18. doi: 10.7150/thno.13099. eCollection 2015. Theranostics. 2015. PMID: 26681985 Free PMC article.
Cited by
-
Nanomaterials in Targeting Cancer Cells with Nanotherapeutics: Transitioning Towards Responsive Systems.Curr Pharm Des. 2024;30(38):3018-3037. doi: 10.2174/0113816128317407240724065912. Curr Pharm Des. 2024. PMID: 39143881 Review.
-
Radiolabeling, Quality Control and In Vivo Imaging of Multimodal Targeted Nanomedicines.Pharmaceutics. 2022 Dec 1;14(12):2679. doi: 10.3390/pharmaceutics14122679. Pharmaceutics. 2022. PMID: 36559172 Free PMC article.
-
Biomimetic Ghost Nanomedicine-Based Optotheranostics for Cancer.Nano Lett. 2024 Jul 10;24(27):8217-8231. doi: 10.1021/acs.nanolett.4c01534. Epub 2024 Jun 7. Nano Lett. 2024. PMID: 38848540 Free PMC article. Review.
-
In vivo active-targeting fluorescence molecular imaging with adaptive background fluorescence subtraction.Front Oncol. 2023 Mar 14;13:1130155. doi: 10.3389/fonc.2023.1130155. eCollection 2023. Front Oncol. 2023. PMID: 36998445 Free PMC article.
-
A novel approach to double-strand DNA break analysis through γ-H2AX confocal image quantification and bio-dosimetry.Sci Rep. 2024 Nov 11;14(1):27591. doi: 10.1038/s41598-024-76683-5. Sci Rep. 2024. PMID: 39528587 Free PMC article.
References
-
- Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011;44(10):1029–1038. - PubMed
-
- Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012;30(21):2585–2592. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources